Cargando…

YES, a novel therapeutic target in hepatocellular carcinoma

Identification of dominant, actionable oncogenic signaling pathways is key to guide the development of new targeted treatments for advanced-stage hepatocellular carcinoma (HCC). We have recently unveiled a novel YES-YAP/TAZ signaling axis involved in liver cancer development. Our study identifies th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lapouge, Marjorie, Meloche, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Author’s Views
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067521/ https://www.ncbi.nlm.nih.gov/pubmed/35529900 http://dx.doi.org/10.1080/23723556.2022.2069993

Ejemplares similares

Lung specific X protein as a novel therapeutic target for lung cancer
por: Zheng, Xiaohu, et al.
Publicado: (2015)

Cisd2 haploinsufficiency: A driving force for hepatocellular carcinoma
por: Shen, Zhao-Qing, et al.
Publicado: (2018)

Tricking an ancient immune function to eradicate hepatocellular carcinoma
por: Miyazaki, Toru, et al.
Publicado: (2015)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma
por: Cariani, Elisabetta, et al.
Publicado: (2013)

Impact of multiplicity of functional KIR-HLA compound genotypes on hepatocellular carcinoma
por: Tanimine, Naoki, et al.
Publicado: (2015)

The adenosinergic system in cancer: Key therapeutic target
por: Sorrentino, Rosalinda, et al.
Publicado: (2013)

Immune surveillance of pre-cancerous senescent hepatocytes limits hepatocellular carcinoma development
por: Yevsa, Tetyana, et al.
Publicado: (2012)

High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored?
por: Lugade, Amit A, et al.
Publicado: (2013)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Tumors induce immune tolerance through activation of β-catenin/TCF4 signaling in dendritic cells: A novel therapeutic target for cancer immunotherapy
por: Suryawanshi, Amol, et al.
Publicado: (2015)

Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis
por: Hurchla, Michelle A., et al.
Publicado: (2012)

Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies
por: Lu, Yong, et al.
Publicado: (2013)

Targeting MDSCs enhance therapeutic vaccination responses against lung cancer
por: Srivastava, Minu K., et al.
Publicado: (2012)

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer
por: Erstad, Derek J., et al.
Publicado: (2017)

DKK1 as a novel target for myeloma immunotherapy
por: Qian, Jianfei, et al.
Publicado: (2012)

Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
por: Rossig, Claudia
Publicado: (2012)

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target
por: Noman, Muhammad Zaeem, et al.
Publicado: (2018)

Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
por: Rathore, Richa, et al.
Publicado: (2021)

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
por: Calabrò, Luana, et al.
Publicado: (2014)

Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
por: Cioffi, Michele, et al.
Publicado: (2012)

Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade
por: Liu, Jiao, et al.
Publicado: (2022)

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma
por: Soriani, Alessandra, et al.
Publicado: (2013)

Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond
por: Urbanska, Katarzyna, et al.
Publicado: (2012)

ImmTACs: Novel bi-specific agents for targeted cancer therapy
por: Oates, Joanne, et al.
Publicado: (2013)

Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease
por: Sawant, Anandi, et al.
Publicado: (2013)

Humanizing mice for the identification of novel anticancer lipids targeting iNKT cells
por: Wen, Xiangshu, et al.
Publicado: (2013)

GD2 and GD3 synthase: novel drug targets for cancer therapy
por: Sphyris, Nathalie, et al.
Publicado: (2015)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
por: Shen, Li, et al.
Publicado: (2012)

KAT2-mediated PLK4 acetylation contributes to genomic stability by preserving centrosome number
por: Fournier, Marjorie, et al.
Publicado: (2016)

The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
por: Giuliano, Sandy, et al.
Publicado: (2014)

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2013)

DDR1 inhibition as a new therapeutic strategy for colorectal cancer
por: Sirvent, Audrey, et al.
Publicado: (2018)

Escape from senescence: revisiting cancer therapeutic strategies
por: Zampetidis, Christos P., et al.
Publicado: (2022)

Acute myeloid leukemia therapeutics: CARs in the driver’s seat
por: Mardiros, Armen, et al.
Publicado: (2013)

Antibody-based therapeutics against components of the IGF system
por: Feng, Yang, et al.
Publicado: (2012)

Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
por: Codarri Deak, Laura, et al.
Publicado: (2023)

TG4010: A therapeutic vaccine against MUC1 expressing tumors
por: Limacher, Jean-Marc, et al.
Publicado: (2012)

Prostate cancer: Important steps and considerations in the design of therapeutic vaccines
por: McArdle, Stephanie EB, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6rm5mjjacqdo9ds26l51ct530d